ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Up – Here’s What Happened

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) gapped up before the market opened on Monday . The stock had previously closed at $76.28, but opened at $82.30. ANI Pharmaceuticals shares last traded at $84.8250, with a volume of 115,338 shares.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Barclays began coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target for the company. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. HC Wainwright upped their target price on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Finally, Guggenheim boosted their price objective on ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $102.14.

ANI Pharmaceuticals Stock Performance

The company has a market capitalization of $1.91 billion, a P/E ratio of 52.17 and a beta of 0.51. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The company’s fifty day moving average is $82.37 and its 200 day moving average is $83.54.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The firm had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. During the same period last year, the company earned $1.34 earnings per share. The business’s revenue for the quarter was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Renee P. Tannenbaum sold 1,800 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $81.15, for a total transaction of $146,070.00. Following the sale, the director owned 25,157 shares of the company’s stock, valued at approximately $2,041,490.55. This represents a 6.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Patrick D. Walsh sold 8,643 shares of the business’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $86.88, for a total transaction of $750,903.84. Following the transaction, the director owned 61,405 shares of the company’s stock, valued at $5,334,866.40. This trade represents a 12.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 28,101 shares of company stock valued at $2,453,063 in the last three months. Insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the first quarter valued at $28,000. Hantz Financial Services Inc. lifted its position in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 510 shares in the last quarter. Newbridge Financial Services Group Inc. increased its position in shares of ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 400 shares during the period. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals in the second quarter worth about $50,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.